Venous thromboembolism (VTE) is a common and life-threatening complication in patients with cancer. The incidence of cancer-associated VTE varies depending on cancer type, disease stage, time since diagnosis and treatment status. Management can be challenging because these patients are often also at increased bleeding risk.
Clinical trials have found that the direct oral anticoagulants (DOACs) rivaroxaban and apixaban have comparable efficacy and safety to low molecular weight heparin (LMWH) in treating VTE in patients with cancer.
Current clinical guidelines recommend considering a DOAC both for initial treatment and for short- and long-term treatment of people with active cancer and confirmed proximal DVT or PE.
This program will help improve your skills and knowledge when diagnosing and treating DVT in patients with cancer.
Also watch Expert Panel Discussion Cancer-associated Thrombosis “What GP’s need to know”.
This educational activity was developed by MDBriefCase at the request, and with funding from BMS & Pfizer Alliance.